Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

NCT03010358 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Anemia
B-Cell Prolymphocytic Leukemia
Grade 1 Follicular Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Hairy Cell Leukemia
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma
Richter Syndrome

Interventions

DRUG: Entospletinib
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Obinutuzumab
OTHER: Pharmacological Study

Sponsor

Alexey Danilov, MD

Collaborators

[object Object]
[object Object]